Clinical implications and risk factors of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae infection in children: A case-control retrospective study in a medical center in southern Taiwan

Journal of Microbiology, Immunology and Infection

Volumn 40, Issue 3, 2007, Pages 248-254

  Kuo, Kuang Che ^a   Shen, Yea Huei ^a   Hwang, Kao Pin ^a,b  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Beta lactam resistance; Beta lactamases; Carbapenems; Klebsiella pneumoniae; Risk factors

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; CARBAPENEM; CEFTAZIDIME; CIPROFLOXACIN; EXTENDED SPECTRUM BETA LACTAMASE; FLOMOXEF; METRONIDAZOLE; TEICOPLANIN; VANCOMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BACTERIUM ISOLATE; CASE CONTROL STUDY; CENTRAL VENOUS CATHETER; CLINICAL EXAMINATION; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG EXPOSURE; ENTEROBACTER INFECTION; FEMALE; HOSPITALIZATION; HUMAN; KLEBSIELLA RHINOSCLEROMATIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; NASOGASTRIC TUBE; RETROSPECTIVE STUDY; RISK FACTOR; TAIWAN;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CASE-CONTROL STUDIES; CEPHALOSPORINS; CHILD; CHILD, PRESCHOOL; COMORBIDITY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; LENGTH OF STAY; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; TAIWAN;

EID: 34948866741     PISSN: 16841182     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992-April 2000, issued June 2000. Am J Infect Control. 2000;28:429-48.
2. Medeiros AA. Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics. Clin Infect Dis. 1997;24(Suppl. 1):S19-45.
3. Philippen A, Labia R, Jacoby G. Extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 1989;33:1131-6.
4. Jacoby GA, Medeiros AA. More extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 1991;35:1697-704.
5. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother. 1995;39:1211-33.
6. Philippen A, Arlet G, Lagrange PH. Origin and impact of plasmid-mediated extended-spectrum beta-lactamases. Eur J Clin Microbiol Infect Dis. 1994;13(Suppl 1):S17-29.
7. Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection. 1983;11:315-7.
8. Lucet JC, Chevret S, Deere D, Vanjak D, Macrez A, Bedos JP, et al. Outbreak of multiply resistant enterobacteriaceae in an intensive care unit: epidemiology and risk factors for acquisition. Clin Infect Dis. 1996;22:430-6.
9. Pena C, Pujol M, Ardanuy C, Ricart A, Pallares R, Linares J, et al. Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 1998;42:53-8.
10. Chanal C, Sirot D, Romaszko JP, Bret L, Sirot J. Survey of prevalence of extended-spectrum beta-lactamases among enterobacteriaceae. J Antimicrob Chemother. 1996;38:127-32.
11. Kim YK, Pai H, Lee HJ, Park SE, Choi EH, Kim J, et al. Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents Chemother. 2002;46:1481-91.
12. Paterson DL, Ko WC, Von Gottberg A, Casellas JM, Mulazimoglu L, Klugman KP, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol. 2001;39:2206-12.
13. Stone PW, Gupta A, Loughrey M, Della-Latta P, Cimiotti J, Larson E, et al. Attributable costs and length of stay of an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae outbreak in a neonatal intensive care unit. Infect Control Hosp Epidemiol. 2003;24:601-6.
14. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis. 2001;32: 1162-71.
15. National Committee for Clinical Laboratory Standards (NCCLS). Performance standards for antimicrobial susceptibility testing, 11th informational supplement. NCCLS document M100-S11. Wayne, PA: National Committee for Clinical Laboratory Standards; 2001.
16. Brun-Buisson C, Legrand P, Rauss A, Richard C, Montravers F, Besbes M, et al. Intestinal decontamination for control of nosocomial multiresistant gram-negative bacilli. Study of an outbreak in an intensive care unit. Ann Intern Med. 1989;110:873-81.
17. Boo NY, Ng SF, Lim VK. A case-control study of risk factors associated with rectal colonization of extended-spectrum beta-lactamase producing Klebsiella sp. in newborn infants. J Hosp Infect. 2005;61:68-74.
18. Kanafani ZA, Mehio-Sibai A, Araj GF, Kanaan M, Kanj SS. Epidemiology and risk factors for extended-spectrum beta-lactamase-producing organisms: a case control study at a tertiary care center in Lebanon. Am J Infect Control. 2005;33:326-32.
19. Pena C, Pujol M, Ricart A, Ardanuy C, Ayats J, Linares J, et al. Risk factors for faecal carriage of Klebsiella pneumoniae producing extended spectrum beta-lactamase (ESBL-KP) in the intensive care unit. J Hosp Infect. 1997;35:9-16.
20. Piroth L, Aube H, Doise JM, Vincent-Martin M. Spread of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae: are beta-lactamase inhibitors of therapeutic value? Clin Infect Dis. 1998;27:76-80.
21. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial infections. Ann Intern Med. 2004;140:26-32.
22. Rodriguez-Bano J, Navarro MD, Romero L, Martinez-Martinez L, Muniain MA, Perea EJ, et al. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol. 2004;42:1089-94.
23. Menashe G, Borer A, Yagupsky P, Peled N, Gilad J, Fraser D, et al. Clinical significance and impact on mortality of extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates in nosocomial bacteremia. Scand J Infect Dis. 2001; 33:188-93.
24. Kim BN, Woo JH, Kim MN, Ryu J, Kim YS. Clinical implications of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae bacteraemia. J Hosp Infect. 2002;52: 99-106.
25. Du B, Chen D, Liu D, Long Y, Shi Y, Wang H, et al. Restriction of third-generation cephalosporin use decreases infection-related mortality. Crit Care Med. 2003;31:1088-93.
26. Paterson DL, Mulazimoglu L, Casellas JM, Ko WC, Goossens H, Von Gottberg A, et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis. 2000;30:473-8.
27. Zaoutis TE, Goyal M, Chu JH, Coffin SE, Bell LM, Nachamkin I, et al. Risk factors for and outcomes of bloodstream infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in children. Pediatrics. 2005;115:942-9.
28. Colodner R, Rock W, Chazan B, Keller N, Guy N, Sakran W, et al. Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis. 2004;23:163-7.
29. Hansen DS, Gottschau A, Kolmos HJ. Epidemiology of Klebsiella bacteraemia: a case control study using Escherichia coli bacteraemia as control. J Hosp Infect. 1998;38:119-32.
30. Tonkic M, Goic-Barisic I, Punda-Polic V. Prevalence and antimicrobial resistance of extended-spectrum beta-lactamases-producing Escherichia coli and Klebsiella pneumoniae strains isolated in a university hospital in Split, Croatia. Int Microbiol. 2005;8:119-24.
31. Chiu S, Huang YC, Lien RI, Chou YH, Lin TY. Clinical features of nosocomial infections by extended-spectrum beta-lactamase-producing Enterobacteriaceae in neonatal intensive care units. Acta Paediatr. 2005;94:1644-9.
32. Pultz NJ, Stiefel U, Donskey CJ. Effects of daptomycin, linezolid, and vancomycin on establishment of intestinal colonization with vancomycin-resistant enterococci and extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae in mice. Antimicrob Agents Chemother. 2005;49:3513-6.
33. Hoyen CK, Pultz NJ, Paterson DL, Aron DC, Donskey CJ. Effect of parenteral antibiotic administration on establishment of intestinal colonization in mice by Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 2003;47:3610-2.
34. Schiappa DA, Hayden MK, Matushek MG, Hashemi FN, Sullivan J, Smith KY, et al. Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation. J Infect Dis. 1996;174:529-36.
35. Liao CH, Sheng WH, Wang JT, Sun HY, Wang HK, Hsueh PR, et al. In vitro activities of 16 antimicrobial agents against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in two regional hospitals in Taiwan. J Microbiol Immunol Infect. 2006;39:59-66.
36. Jan IS, Hsueh PR, Teng LJ, Ho SW, Luh KT. Antimicrobial susceptibility testing for Klebsiella pneumoniae isolates resistant to extended-spectrum beta-lactam antibiotics. J Formos Med Assoc. 1998;97:661-6.
37. Yu WL, Pfaller MA, Winokur PL, Jones RN. Cefepime MIC as a predictor of the extended-spectrum beta-lactamase type in Klebsiella pneumoniae, Taiwan. Emerg Infect Dis. 2002;8: 522-4.